Condition: Non-Diabetic · Sponsor: Centre Hospitalier Universitaire de la Guadeloupe
In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.
This description comes directly from the study's public registry record.
Valérie HAMONY-SOTER · +590 590 93 46 77 · valerie.soter@chu-guadeloupe.fr
Eunice NUBRET · eunice.nubret@chu-guadeloupe.fr
Always discuss trial participation with your own doctor first.
| Centre Hospitalier Universitaire de la Guadeloupe | Pointe-à-Pitre, Guadeloupe, Guadeloupe | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07233434